摘要
奥马珠单抗是一种重组人源化单克隆抗体,为抗IgE靶向生物制剂,是全球首个获批治疗中至重度支气管哮喘的靶向治疗药物。本文对1例阿司匹林哮喘伴分泌性中耳炎及鼻窦炎患者进行回顾性分析,探讨奥马珠单抗在治疗哮喘及其合并症中的价值,为临床实践提供依据。
Omalizumab,as a biological agent targeting IgE,is a recombinant humanized monoclonal antibody and the first targeted drug approved for treating moderate-to-severe bronchial asthma.By reviewing one case of aspirin-induced asthma complicated with nasosinusitis and otitis media,we discussed the value of omalizumab in the treatment of asthma and its complications,aiming to provide a reference for clinical practice.
作者
汤蕊
雷曙槟
王轶
TANG Rui;LEI Shubin;WANG Yi(Department of Allergy,Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Disease,National Clinical Research Center for Dermatologic and Immunologic Diseases,PUMC Hospital,CAMS and PUMC,Beijing 100730,China;Eight-Year Program of Clinical Medicine,CAMS and PUMC,Beijing 100730,China;Department of Otolaryngology and Head and Neck Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China)
出处
《中国医学科学院学报》
CAS
CSCD
北大核心
2023年第4期699-702,共4页
Acta Academiae Medicinae Sinicae
关键词
奥马珠单抗
哮喘
鼻窦炎
中耳炎
omalizumab
asthma
nasosinusitis
otitis media
